And Big Pharma’s not done cashing in on the weight-loss boom. Drugmakers are readying a new wave of next-level GLP-1 treatments, with several promising candidates in the pipeline. These experimental ...
"Ozempic 2.0" has been floating around online, as a trending nickname for the next generation of weight loss drugs that are in the works.
GLP-1 agonist drugs essentially mimic the hormone’s action. Quite a few have been developed, including semaglutide, ...
Picture this: you wake up in the morning, and the first thing you do is gulp down a few prescribed pills. And after ...
Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.
Pharmaceutical company Eli Lilly is looking to roll out a daily weight loss pill for patients with obesity and type 2 ...
Orforglipron, a GLP-1 drug taken as a pill, achieved positive results in people with obesity and type 2 diabetes, although it ...
The daily pill may provide a more convenient alternative to injections, which patients can find difficult to administer.
The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...
Each year, millions of people turn to diet pills to lose weight. As of 2022, about 15 percent of U.S. adults reported using a weight-loss supplement at some point in their lives. One popular ...
Investor's Business Daily on MSN
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.
Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the party over?
WASHINGTON — Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's new national priority voucher, suggesting it is a strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback